Covidien

To see an up-to date selection of historical analyses and insights on Covidien, visit our new, dynamically updated Company Summary report pages for Covidien.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Covidien are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Covidien, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Event - Milestones from Exalgo approval will boost CombinatoRx's fortunes   (CombinatoRx)   (Invalid Date)
FDA Extends Review of NDA for Exalgo(TM)   (Covidien)   (Invalid Date)
FDA Extends NDA Review for Exalgo(TM) Extended-Release Tablets   (CombinatoRx)   (Invalid Date)
Neuromed Receives FDA Feedback on New Drug Application for Exalgo Extended-Release Tablets   (CombinatoRx)   (Invalid Date)
FDA Discusses Neuromed NDA Application for Exalgo   (Covidien)   (Invalid Date)
Covidien Introduces First FDA-Approved Spine Sealant   (Covidien)   (Invalid Date)
Covidien Submits Label Change for Optimark(TM) Contrast Agent   (Covidien)   (Invalid Date)
FDA Approves Pennsaid(R) Topical Solution   (Covidien)   (Invalid Date)
FDA Approves Pennsaid® Topical Solution   (Nuvo Research)   (Invalid Date)
Covidien Receives FDA Approval for Oral Transmucosal Fentanyl Citrate Product   (Covidien)   (Invalid Date)
Covidien Announces Global Launch of Mallinckrodt(TM) TaperGuard(TM) Line of Endotracheal Tubes   (Covidien)   (Invalid Date)
Covidien Introduces Revolutionary Wound Closure Device   (Covidien)   (Invalid Date)
Covidien Receives FDA Clearance for its Mallinckrodt(TM) TaperGuard(TM) Evac Endotracheal Tube   (Covidien)   (Invalid Date)
FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets   (CombinatoRx)   (Invalid Date)
CombinatoRx Stock Trading Halted Today   (CombinatoRx)   (Invalid Date)
FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets   (Covidien)   (Invalid Date)
CombinatoRx and Neuromed Announce Posting of Briefing Documents for FDA Advisory Committee   (CombinatoRx)   (Invalid Date)
DuraSeal(TM) Spine Sealant Receives FDA Approval   (Covidien)   (Invalid Date)
Covidien Launches NeoMode(TM) Software Upgrade for Puritan Bennett 840(TM) Ventilator   (Covidien)   (Invalid Date)
FDA Extends Review of Pennsaid(R) Diclofenac Sodium Topical Solution   (Covidien)   (Invalid Date)
FDA Extends Review of Pennsaid®diclofenac Sodium Topical Solution   (Nuvo Research)   (Invalid Date)
Covidien Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit   (Covidien)   (Invalid Date)
Covidien Launches Alarm Management System for the Nellcor(TM) OxiMax(TM) N-600x(TM) Pulse Oximeter   (Covidien)   (Invalid Date)
Covidien Launches Duet TRS(TM) Reload with Tissue Reinforcement   (Covidien)   (Invalid Date)
Covidien Launches SILS(TM) Port Multiple Instrument Access Port   (Covidien)   (Invalid Date)
Covidien Announces U.S. Launch of Puritan Bennett 540(TM) Portable Ventilator   (Covidien)   (Invalid Date)
Covidien Receives FDA Clearance for the Nellcor(TM) OxiMax(TM) N-600x(TM) Pulse Oximeter with OxiMax SPD(TM) Alert   (Covidien)   (Invalid Date)
Neuromed Announces Exalgo (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial   (Neuromed Pharmaceuticals)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.